Polymorphic repeat in AIB1 does not alter breast cancer risk.
STATEMENT OF FINDINGS: We assessed the association between a glutamine repeat polymorphism in AIB1 and breast cancer risk in a case-control study (464 cases, 624 controls) nested within the Nurses' Health Study cohort. We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor characteristics. These findings suggest that AIB1 repeat genotype does not influence postmenopausal breast cancer risk among Caucasian women in the general population.
Haiman
C A
CA
Channing Laboratory, Department of Medicine, Harvard School of Public Health, 191 Longwood Avenue, Boston, MA 02115, USA. nhchr@channing.harvard.edu
Hankinson
S E
SE
Spiegelman
D
D
Colditz
G A
GA
Willett
W C
WC
Speizer
F E
FE
Brown
M
M
Hunter
D J
DJ
D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics; D016022:Case-Control Studies; D017931:DNA Primers / Q000737:chemistry; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005838:Genotype; D005973:Glutamine / Q000235:genetics; D006801:Humans; D015810:Linkage Disequilibrium; D018895:Microsatellite Repeats; D008875:Middle Aged; D056921:Nuclear Receptor Coactivator 3; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012307:Risk Factors; D017422:Sequence Analysis, DNA; D014157:Transcription Factors / Q000235:genetics*
D017931:DNA Primers; D004273:DNA, Neoplasm; D014157:Transcription Factors; D005973:Glutamine; D056921:Nuclear Receptor Coactivator 3